Today: 23 May 2026
Nvidia, AMD or Intel? CES 2026 AI chip rollouts sharpen 2026 stock callsLAS VEGAS,

Nvidia, AMD or Intel? CES 2026 AI chip rollouts sharpen 2026 stock callsLAS VEGAS,

January 7, 2026, 07:31 PST

  • Nvidia says its next-generation Vera Rubin platform is in “full production” as it lines up cloud and AI customers
  • AMD rolled out new MI455 and MI440X chips and previewed a 2027 MI500 series as it presses its OpenAI ties
  • Analysts’ targets still favor Nvidia and AMD, while Intel draws mixed calls despite a fresh upgrade

Nvidia’s next-generation Vera Rubin platform is now in “full production,” CEO Jensen Huang said at CES in Las Vegas, giving investors a sharper sense of when the hardware driving the AI boom is due to land.

Why it matters now: CES has turned into a pit stop on the chip industry’s road map. Cloud firms and big AI developers show up looking for the next wave of data center gear, kicking the tires ahead of earnings season. But the stakes keep rising as companies move from training giant models to running them at scale for consumers and businesses.

Analysts are tracking those launches closely, trying to figure out who comes out on top in 2026. Nvidia and AMD are still viewed as the cleanest bets on demand for graphics processing units (GPUs) — chips used to train and run AI models — and “inference,” the step where a trained model generates answers. Intel has also crept back onto the radar, though investors don’t appear fully sold.

Huang said Rubin’s flagship server will carry 72 GPUs and 36 central processing units (CPUs), and can be linked into “pods” holding more than 1,000 Rubin chips. He said the platform could boost the efficiency of generating “tokens” — the chunks of text AI systems process — by 10 times, and add “context memory storage” so chatbots can handle long prompts faster. https://www.reuters.com/world/china/nvidia…

AMD used CES to unveil its MI455 AI processors aimed at server racks bought by customers such as ChatGPT maker OpenAI. It also rolled out MI440X, pitched at companies that prefer running AI on their own systems rather than on purpose-built clusters. CEO Lisa Su pointed to its “Helios” rack-scale design as a blueprint for “yotta-scale” computing, saying a single rack can deliver up to 3 AI exaflops — a measure of computing power. https://www.reuters.com/business/amd-unvei… https://www.amd.com/en/newsroom/press-rele…

On Wall Street, Bernstein analyst Stacy Rasgon said Rubin was “in full production, and looks like a monster,” TipRanks reported. TipRanks also flagged Piper Sandler analyst Harsh Kumar, who reiterated a Buy on AMD with a $280 price target. Based on TipRanks data, Nvidia’s average price target suggested roughly 40% upside, compared with about 32% for AMD, while Intel’s consensus target pointed to a slight downside. https://www.tipranks.com/news/amd-vs-nvda-…

In a Zacks commentary carried on Nasdaq, Nvidia has seen the sharper upward revisions to earnings estimates, while AMD’s projections have been mostly flat in recent weeks. Zacks projected AMD earnings of $3.96 a share for FY2025 and $6.26 for FY2026. For Nvidia, it penciled in $4.66 for FY2026 and $7.24 for FY2027. AMD is set to report on Feb. 3, and Nvidia is due on Feb. 25.

Intel, meanwhile, unveiled Core Ultra Series 3 laptop processors made on its 18A manufacturing process, and said pre-orders would start Jan. 6, with systems shipping worldwide from Jan. 27. Melius Research analyst Ben Reitzes upgraded Intel to Buy and lifted his price target to $50, MarketWatch reported, arguing the foundry and packaging story could end up mattering more in 2026 than investors expect.

Stock Market Today

  • Haemonetics Q1 Earnings Beat Estimates Amid Strong Medical Devices Sector Performance
    May 22, 2026, 10:52 PM EDT. Haemonetics (NYSE:HAE) posted a robust Q1 with revenues of $346.4 million, up 4.8% year on year and exceeding analyst forecasts by 2.6%. The medical devices & supplies specialty sector outperformed expectations, with revenues beating consensus by 5.2% overall. Haemonetics shares rose 10.6% post-earnings to $58.27, reflecting investor confidence. Industry growth drivers include an aging population increasing demand for blood-related medical products and advances in digital health technology, while challenges remain from pricing pressures and regulatory demands. The sector saw steady stock performance, up 3.6% on average following earnings releases. STAAR Surgical also delivered strong results, highlighting sector momentum.

Latest articles

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

23 May 2026
The Dow closed at a record 50,579.70 on Friday, while the S&P 500 notched its eighth straight weekly gain. After-hours trading saw SPY, QQQ, DIA, and IWM all move lower. U.S. markets will be closed Monday for Memorial Day. Investors await Thursday’s inflation data.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

23 May 2026
IREN shares fell 2.1% to $56.83 Friday, ending a two-day rally but closing the week up 7.4%. The stock’s moves follow a $3.4 billion AI cloud deal with Nvidia and a $3 billion convertible note offering. March-quarter revenue dropped to $144.8 million, with a net loss of $247.8 million. U.S. markets close Monday for Memorial Day; trading resumes Tuesday.
AXT stock reaches record; investors weigh risk to rally

AXT stock reaches record; investors weigh risk to rally

23 May 2026
AXT shares jumped 16.37% to $140.83 on Friday, hitting a 52-week high and trading above all recent analyst targets. The surge followed strong demand for AI-linked optical networking hardware and a sharp rise in indium phosphide orders. First-quarter revenue climbed to $26.9 million, with gross margin turning positive. Management forecast Q2 profitability and a backlog over $100 million.
Palantir stock ticks higher as Truist starts coverage with $223 target, valuation stays in play
Previous Story

Palantir stock ticks higher as Truist starts coverage with $223 target, valuation stays in play

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop